二甲双胍与生活方式对糖尿病预防计划及其结局研究中冠状动脉钙化的长期影响
在3234例糖尿病前期患者中开展的DPP/DPPOS长期干预研究显示,经平均14年随访,生活方式与安慰剂组冠状动脉钙化(CAC)无差异;二甲双胍组男性CAC严重程度和存在率显著低于安慰剂组,女性未见二甲双胍效应。
要点
- 生活方式干预与安慰剂组相比,男女CAC均无显著差异。
- 二甲双胍组男性CAC严重程度和存在率显著低于安慰剂组。
- 二甲双胍对女性CAC未见显著影响。
核心结论
- 二甲双胍可能对糖尿病前期及早期糖尿病男性患者的冠状动脉粥样硬化具有保护作用。
研究设计与样本
- DPP/DPPOS为长期干预研究,纳入3234例糖尿病前期受试者(平均±SD年龄64±10岁),随机接受生活方式、二甲双胍或安慰剂干预3.2年。
- DPPOS对所有参与者提供周期性小组生活方式课程,原二甲双胍组继续服用二甲双胍。
- 在平均14年随访后,对2029例参与者进行冠状动脉钙化(CAC)测量以评估亚临床动脉粥样硬化。
主要发现
- 生活方式组与安慰剂组相比,男女CAC均无显著差异。
- 男性中,二甲双胍组较安慰剂组年龄调整平均CAC严重程度降低(39.5 vs 66.9 Agatston单位,P=0.04),CAC存在率降低(75% vs 84%,P=0.02)。
- 女性中未观察到二甲双胍对CAC的显著效应。
- 多因素分析显示,男性中二甲双胍效应不受人口学、人体测量学或代谢因素、糖尿病发生以及他汀类药物使用与否的影响。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the reduced incidence of coronary heart disease with intensive risk factor management, people with diabetes mellitus and prediabetes remain at increased coronary heart disease risk. Diabetes prevention interventions may be needed to reduce coronary heart disease risk. This approach was examined in the DPP (Diabetes Prevention Program) and the DPPOS (Diabetes Prevention Program Outcome Study), a long-term intervention study in 3234 subjects with prediabetes (mean±SD age, 64±10 years) that showed reduced diabetes risk with lifestyle and metformin compared with placebo over 3.2 years. METHODS: The DPPOS offered periodic group lifestyle sessions to all participants and continued metformin in the originally randomized metformin group. Subclinical atherosclerosis was assessed in 2029 participants with coronary artery calcium (CAC) measurements after an average of 14 years of follow-up. The CAC scores were analyzed continuously as CAC severity and categorically as CAC presence (CAC score >0) and reported separately in men and women. RESULTS: There were no CAC differences between lifestyle and placebo intervention groups in either sex. CAC severity and presence were significantly lower among men in the metformin versus the placebo group (age-adjusted mean CAC severity, 39.5 versus 66.9 Agatston units, P=0.04; CAC presence, 75% versus 84%, P=0.02), but no metformin effect was seen in women. In multivariate analysis, the metformin effect in men was not influenced by demographic, anthropometric, or metabolic factors; by the development of diabetes mellitus; or by use/nonuse of statin therapy. CONCLUSIONS: Metformin may protect against coronary atherosclerosis in prediabetes and early diabetes mellitus among men. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00038727.
引用
- Goldberg RB, Aroda VR, Bluemke DA, et al. Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium. Circulation. 2017. PMID: 28476766. doi:10.1161/CIRCULATIONAHA.116.025483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。